{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:15:37Z","timestamp":1789010137616,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapsed or refractory (rel\/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel\/ref cHL patients was evaluated at a dose of 25 mg\/d on days 1-21 of a 28-day cycle. Patients remained on lenalidomide until disease progression or an unacceptable adverse event (AE) occurred. Thirty-eight cHL patients were enrolled with a median of 4 (range, 2-9) prior therapies; 87% had undergone prior stem cell transplantation and 55% of patients did not respond to their last prior therapy. Of 36 evaluable patients, responses were 1 complete remission (CR), 6 partial remissions (PRs), and 5 patients with stable disease (SD) for \u2265 6 months resulting in an International Working Committee (IWC) objective overall response rate (ORR) of 19% and a cytostatic ORR of 33%. Decreased chemokine (CCL17 and CCL22) plasma levels at 2 weeks were associated with a subsequent response. The treatment was well tolerated, and the most common grade 3\/4 AEs were neutropenia (47%), anemia (29%), and thrombocytopenia (18%). Four patients discontinued lenalidomide because of rash, elevated transaminases\/bilirubin, and cytopenias. We provide preliminary evidence of lenalidomide's activity in patients with rel\/ref cHL, and therefore exploration of lenalidomide in combination with other active agents is warranted. This trial is registered at www.ClinicalTrials.gov as NCT00540007.<\/jats:p>","DOI":"10.1182\/blood-2011-07-362475","type":"journal-article","created":{"date-parts":[[2011,9,22]],"date-time":"2011-09-22T04:58:32Z","timestamp":1316667512000},"page":"5119-5125","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":152,"title":["A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"118","author":[{"given":"Todd A.","family":"Fehniger","sequence":"first","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Trinkaus","sequence":"additional","affiliation":[{"name":"Biostatistics, Washington University School of Medicine, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn J.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Mallinckrodt Institute of Radiology, Alvin J. Siteman Cancer Center, Washington University, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Department of Hematology and The Oncology, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Hurd","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine R.","family":"Keppel","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina D.","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Carson","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Divisions of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111814201268800_B1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MOH.0b013e328302c9d8","article-title":"Modern treatment of Hodgkin lymphoma.","volume":"15","author":"Bartlett","year":"2008","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"2019111814201268800_B2","first-page":"517","article-title":"Salvage regimens for Hodgkin lymphoma.","volume":"6","author":"Cashen","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"issue":"4","key":"2019111814201268800_B3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/10428190902756586","article-title":"Drug development for recurrent and refractory classical Hodgkin lymphoma.","volume":"50","author":"Wildes","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111814201268800_B4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/CCO.0b013e32833d752c","article-title":"Recent advances of IMiDs in cancer therapy.","volume":"22","author":"Li","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"2019111814201268800_B5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies.","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111814201268800_B6","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"34","key":"2019111814201268800_B7","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111814201268800_B8","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent nonHodgkin's Lymphoma.","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019111814201268800_B9","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"36","key":"2019111814201268800_B10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies.","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"2019111814201268800_B11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/asheducation-2005.1.231","article-title":"Immunobiology and pathophysiology of Hodgkin lymphomas.","author":"Poppema","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2019111814201268800_B12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111814201268800_B13","article-title":"International Agency for Research on Cancer.","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","author":"Swerdlow","year":"2008"},{"issue":"5","key":"2019111814201268800_B14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111814201268800_B15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22.","volume":"140","author":"Niens","year":"2008","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111814201268800_B16","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/0008-5472.CAN-05-0100","article-title":"Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.","volume":"65","author":"Weihrauch","year":"2005","journal-title":"Cancer Res"},{"issue":"19","key":"2019111814201268800_B17","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111814201268800_B18","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V112.11.3052.3052","article-title":"Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstract].","volume":"112","author":"Kuruvilla","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111814201268800_B19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2141.2009.07963.x","article-title":"Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.","volume":"148","author":"B\u00f6ll","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111814201268800_B20","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.V116.21.2828.2828","article-title":"Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstract].","volume":"116","author":"Boll","year":"2010","journal-title":"Blood"},{"key":"2019111814201268800_B21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/blood.V116.21.283.283","article-title":"Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma [abstract].","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111814201268800_B22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","article-title":"Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.","volume":"147","author":"Dickinson","year":"2009","journal-title":"Br J Haematol"},{"key":"2019111814201268800_B23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.V116.21.419.419","article-title":"Final analysis: phase II study of oral panobinostat in relapsed\/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant [abstract].","volume":"116","author":"Sureda","year":"2010","journal-title":"Blood"},{"key":"2019111814201268800_B24","doi-asserted-by":"crossref","first-page":"A8507","DOI":"10.1200\/jco.2008.26.15_suppl.8507","article-title":"Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed\/refractory classical Hodgkin lymphoma (HL) [abstract].","volume":"26","author":"Bociek","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111814201268800_B25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"2019111814201268800_B26","unstructured":"Everolimus and lenalidomide in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma (www.ClinicalTrials.gov identifier: NCT01075321). Accessed April 1, 2011 Available from: http:\/ClinicalTrials.gov\/"},{"key":"2019111814201268800_B27","unstructured":"Lenalidomide maintenance therapy post autologous transplant for Hodgkins lymphoma (www.ClinicalTrials.gov identifier: NCT01207921). Accessed April 1, 2011 Available from: http:\/\/ClinicalTrials.gov\/ct2\/show\/NCT01207921?term=NCT01207921&rank=1"},{"key":"2019111814201268800_B28","unstructured":"AVD-Rev in elderly Hodgkin lymphoma patients (www.ClinicalTrials.gov identifier: NCT01056679). Accessed April 1, 2011 Available from: http:\/\/ClinicalTrials.gov\/ct2\/show\/NCT01056679?term=NCT01056679&rank=1"},{"issue":"14","key":"2019111814201268800_B29","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111814201268800_B30","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.","volume":"154","author":"van den Berg","year":"1999","journal-title":"Am J Pathol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/19\/5119\/1345048\/zh804511005119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/19\/5119\/1345048\/zh804511005119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T07:18:15Z","timestamp":1712906295000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/19\/5119\/29364\/A-phase-2-multicenter-study-of-lenalidomide-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,10]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-362475","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,10]]}}}